Skip to content
  • May 27, 2004
  • General

ACADIA Pharmaceuticals Announces Initial Public Offering

SAN DIEGO, May 26 /PRNewswire-FirstCall/ —ACADIA Pharmaceuticals Inc.(Nasdaq: ACAD) today announced the pricing of its initial public offering of5,000,000 shares of common stock at a price of $7.00 per share. All of theshares are being offered by ACADIA. ACADIA also granted to the underwriters athirty-day option to purchase up to an additional 750,000 shares of commonstock to cover over-allotments. The shares have been listed on The NasdaqNational Market under the symbol "ACAD."

Banc of America Securities LLC is acting as sole book-running manager,Piper Jaffray & Co. is acting as co-lead manager and JMP Securities LLC andAdams, Harkness & Hill, Inc. are acting as co-managers for the offering.

The public offering is being made only by means of a prospectus. Copiesof the final prospectus relating to the offering can be obtained from Banc ofAmerica Securities LLC, Attention: Syndicate Department, 100 West 33rd Street,3rd Floor, New York, New York 10001, 646-733-4166,email: DL-ProspectusDistribution@bofasecurities.com.

This press release shall not constitute an offer to sell or thesolicitation of an offer to buy, nor shall there be any sale of thesesecurities in any jurisdiction in which such offer, solicitation or sale wouldbe unlawful prior to the registration or qualification under the securitieslaws of any such jurisdiction.

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on thediscovery, development and commercialization of small molecule darugs for thetreatment of central nervous system disorders.

For further information please contact: Uli Hacksell, Ph.D., ChiefExecutive Officer, or Thomas H. Aasen, Vice President and Chief FinancialOfficer, both of ACADIA Pharmaceuticals Inc., +1-858-558-2871

SOURCE ACADIA Pharmaceuticals Inc.-0- 05/26/2004/CONTACT: Uli Hacksell, Ph.D., Chief Executive Officer, or Thomas H.Aasen, Vice President and Chief Financial Officer, both of ACADIAPharmaceuticals Inc., +1-858-558-2871//Web site: http://www.acadia-pharm.com /(ACAD)CO: ACADIA Pharmaceuticals Inc.ST: CaliforniaIN: HEA MTC BIOSU: OFRLP—LAW133 —4250 05/26/2004 21:52 EDT http://www.prnewswire.com—>

Important Note

You are now being redirected

You are now leaving acadia.com

You are about to leave acadia.com. You will be redirected to a third party website not affiliated with Acadia Pharmaceuticals Inc.
Do you want to continue?

You are leaving our {{LEAVING_REGION}} website and going to our {{ENTERING_REGION}} website, which is in {{ENTERING_LANGUAGE}}.
The information you are about to be referred to may not comply with the local regulatory requirements.
Do you want to continue?

You are now being directed to another Acadia website that contains information about specific treatment(s).
Do you want to continue?

Continue